Company Devonian Health Group Inc.

GSD

CA2518341078

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:01:37 2024-04-23 pm EDT			5-day change	1st Jan Change
0.22 ^CAD	0.00%		0.00%	+51.72%

Mar. 28	Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
Mar. 14	Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7%	MT

Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.

Number of employees: 7

CAD in Million	2024	Weight	Delta
Pharmaceutical 100.0 %	2	100.0 %	-

CAD in Million	2024	Weight	Delta
Canada 100.0 %	2	100.0 %	-

Managers	Title	Age	Since
Luc Grégoire CEO	Chief Executive Officer	64	23-03-16
Colette Laurin DFI	Director of Finance/CFO	-	15-12-27
Pascal Brabant CTO	Chief Tech/Sci/R&D Officer	-	-
Daniel Bouthillier CTO	Chief Tech/Sci/R&D Officer	-	-
André Boulet CTO	Chief Tech/Sci/R&D Officer	-	15-03-26
Nathalie Boucher PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
André Boulet CTO	Chief Tech/Sci/R&D Officer	-	15-03-26
Luc Grégoire CEO	Chief Executive Officer	64	23-03-16
Kathryn Gregory BRD	Director/Board Member	62	Feb. 27
Jean Forcione BRD	Director/Board Member	58	23-05-11
David Baker CHM	Chairman	60	23-05-11
Louis Flamand BRD	Director/Board Member	-	17-05-24
Edouard Dahl BRD	Director/Board Member	-	23-05-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	148,222,531	127,172,676 ( 85.80 %)	0	85.80 %

Name	Equities	%	Valuation
André Boulet 13.69 %	20,083,189	13.69 %	5 M $
Jean Forcione 0.4543 %	666,667	0.4543 %	176 667 $
Pierre Montanaro 0.2045 %	299,999	0.2045 %	79 500 $
Richard Provencher 0.1032 %	151,486	0.1032 %	40 144 $
Colette Laurin 0.0227 %	33,333	0.0227 %	8 833 $
Luc Grégoire 0.000000 %	0	0.000000 %	- $
Kathryn Gregory 0.000000 %	0	0.000000 %	- $
David Baker 0.000000 %	0	0.000000 %	- $
Ashish Chabria 0.000000 %	0	0.000000 %	- $
Edouard Dahl 0.000000 %	0	0.000000 %	- $

Devonian Health Group, Inc.

360, rue des Entrepreneurs

G5V 4T1, Montmagny

http://www.groupedevonian.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
DEVONIAN HEALTH GROUP INC.	+51.72%	23.82M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals